加载中...

Bristol-Myers Squibb Company (BMY) 财务分析 | 估值·财报 | 100Baggers.club

Bristol-Myers Squibb Company

BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

加载图表中...

加载图表中...

📊 估值

关键估值指标

EV/EBITDA (TTM)

i

Enterprise Value, EBITDA and Ratio

EV/EBIT (TTM)

i

Enterprise Value, EBIT and Ratio

EV/Sales (TTM)

i

Enterprise Value, Revenue and Ratio

P/E Ratio (TTM)

i

Market Cap, Net Income and Ratio

P/B Ratio (Quarterly)

i

Market Cap, Book Value and Ratio

FCF Yield (TTM)

i

FCF, Enterprise Value and Yield

PR Profit Ratio (PPM)

i

PE Ratio, ROE and Profit Ratio (PR = PE / ROE)

📈 成长

营收、盈利和每股成长指标

Revenue (Quarterly)

i

Quarterly Revenue

Revenue/Share (Quarterly)

i

Revenue Per Share

Net Income (Quarterly)

i

Quarterly Net Income

EPS (Quarterly)

i

Earnings Per Share

Gross Profit/Share (Quarterly)

i

Gross Profit Per Share

OCF/Share (Quarterly)

i

Operating Cash Flow Per Share

FCF/Share (Quarterly)

i

Free Cash Flow Per Share

Operating Leverage (YoY)

i

Change in Operating Income / Change in Revenue

💰 盈利

利润率和净资产收益率

Gross Margin (TTM)

i

Revenue, Gross Profit and Gross Margin

Operating Margin (TTM)

i

Revenue, Operating Income and Operating Margin

Net Profit Margin (TTM)

i

Revenue, Net Income and Net Profit Margin

ROE (TTM)

i

Equity, Net Income and Return on Equity

ROA (TTM)

i

Assets, Net Income and Return on Assets

ROTCE - Return on Tangible Common Equity (TTM)

i

Net Income, Tangible Common Equity and ROTCE

OCF Margin (TTM)

i

Revenue, Operating Cash Flow and OCF Margin

FCF Margin (TTM)

i

Revenue, Free Cash Flow and FCF Margin

💵 现金质量

现金流质量和转换指标

OCF/NI Ratio (TTM)

i

Operating Cash Flow, Net Income and Ratio

FCF/NI Ratio (TTM)

i

Free Cash Flow, Net Income and Ratio

OCF/Capex (TTM)

i

Operating Cash Flow, Capex and Coverage Ratio

OCF/SBC (TTM)

i

Operating Cash Flow, SBC and Coverage Ratio

🛡️ 财务韧性

债务、流动性和财务健康度

Debt/Equity (quarterly)

i

Total Debt, Total Equity and Debt/Equity Ratio

EBITDA/Net Debt (TTM)

i

EBITDA, Net Debt and Coverage Ratio

Interest Coverage (TTM)

i

EBIT, Interest Expense and Coverage Ratio

Current Ratio (quarterly)

i

Current Assets, Current Liabilities and Current Ratio

Quick Ratio (quarterly)

i

Quick Assets, Current Liabilities and Quick Ratio

Altman Z-Score

i

Financial Distress Prediction Model

⚙️ 运营与资本效率

资产利用率、营运资本、ROIC和资本效率

ROIC (TTM)

i

NOPAT, Invested Capital and Return on Invested Capital

ROCE - Return on Capital Employed (TTM)

i

EBIT, Capital Employed and Return on Capital Employed

Asset Turnover (TTM)

i

Revenue, Total Assets and Turnover Ratio

CapEx/Depreciation - Investment Intensity (TTM)

i

CapEx, Depreciation and Ratio (>1=Expansion, <1=Contraction)

R&D/Gross Profit - R&D Intensity (TTM)

i

R&D Expenses, Gross Profit and Ratio

SG&A/Revenue - SG&A Efficiency (TTM)

i

SG&A Expenses, Revenue and Ratio

Cash Conversion Cycle (TTM)

i

DSO + DIO - DPO (in days)

DSO - Days Sales Outstanding (TTM)

i

Average Receivables and Days Sales Outstanding

DIO - Days Inventory Outstanding (TTM)

i

Average Inventory and Days Inventory Outstanding

DPO - Days Payables Outstanding (TTM)

i

Average Payables and Days Payables Outstanding

Goodwill/Assets (Quarterly)

i

Goodwill as % of Total Assets

🎁 股东回报

股息、股票回购、稀释和内部人交易活动

Dividend Yield (TTM)

i

Dividend Per Share, Share Price and Dividend Yield

Buyback Yield (TTM)

i

Net Buyback and Buyback Yield

Buyback Yield (3 Years)

i

Net Buyback 3Y and Buyback Yield 3Y

Dilution Rate (1 Year)

i

Current Shares, 1Y Ago Shares and Dilution Rate

Dilution Rate (3 Years)

i

Current Shares, 3Y Ago Shares and Dilution Rate

SBC Offset Rate (TTM)

i

Buyback / Stock-Based Comp and SBC Ratio

Insider Activity Rate (TTM)

i

Insider Net Buying and Activity Rate

利润瀑布图分析

加载图表中...

P

盈利能力指标

Gross Profit Margini毛利率

70.22%

毛利润 = $8.07B

营业收入 = $11.49B

Operating Profit Margini营业利润率

28.47%

营业利润 = $3.27B

营业收入 = $11.49B

EBITDA MarginiEBITDA利润率

32.27%

EBITDA = $3.71B

营业收入 = $11.49B

EBIT MarginiEBIT利润率

28.47%

EBIT = $3.24B

营业收入 = $11.49B

Net Profit Margini净利率

23.31%

净利润 = $2.68B

营业收入 = $11.49B

Pretax Profit Margini税前利润率

28.20%

税前利润 = $3.24B

营业收入 = $11.49B

E

运营效率指标

Interest Coveragei利息保障倍数

10.33x

EBIT (TTM) = $10.49B

利息费用 (TTM) = $1.02B

4.0x

4.3x

5.1x

7.1x

10.3x

SG&A / Revenuei销管费率

14.07%

销售及管理费用 = $1.62B

营业收入 = $11.49B

R&D / Revenuei研发占比

23.06%

研发费用 = $2.65B

营业收入 = $11.49B

R

回报率指标 (TTM)

ROAi总资产回报率

8.13%

净利润 = $7.28B

平均总资产 = $89.45B

ROEi净资产收益率

38.84%

净利润 = $7.28B

平均股东权益 = $18.73B

ROICi投入资本回报率

17.36%

NOPAT (TTM) = $9.43B

平均投入资本 = $54.32B

(NOPAT = 营业利润 × (1 - 有效税率))

(平均投入资本 = (本期IC + 去年同期IC) / 2)

Revenue Growthi营收增长率

2.57%

当期营收 = $11.49B

去年同期营收 = $11.20B

-5.6%

+0.6%

+2.8%

+1.3%

+2.6%

Operating Cash Flow/Sharei每股经营现金流

$6.51

经营现金流 = $13.31B

流通股数 = 2.04B

$7.03

$7.80

$8.16

$6.94

$6.51

综合分析

利润表项目	同比增长	当季数据	趋势
营业收入	+2.6%	$11.49B	↑
毛利	+9.9%	$8.07B, 70.22%	↑
营业利润	-7.1%	$3.27B, 28.47%	↓
EBITDA	-17.2%	$3.71B, 32.27%	↓
税前利润	+9.1%	$3.24B, 28.20%	↑
净利润	+9.0%	$2.68B, 23.31%	↑
稀释每股收益	+9.2%	1.31	↑

加载图表中...

L

流动性指标

Current Ratioi流动比率

1.42

正常

流动资产 = $27.21B

流动负债 = $19.16B

Quick Ratioi速动比率

1.28

健康

速动资产 = $24.45B

流动负债 = $19.16B

Cash Ratioi现金比率

0.55

健康

现金及等价物 = $10.49B

流动负债 = $19.16B

Cash Ratio = (Cash + Short-term Investments) / Current Liabilities

L

杠杆指标

Debt to Equityi债务权益比

2.22

关注

总债务 = $44.46B

总权益 = $20.07B

Liabilities to Assetsi资产负债率 (总负债)

76.8%

关注

总负债 = $66.37B

总资产 = $86.48B

Equity Multiplieri权益乘数

4.31

关注

总资产 = $86.48B

总权益 = $20.07B

E

效率指标

Asset Turnoveri总资产周转率

0.54

正常

营收 (TTM) = $48.48B

平均总资产 = $89.45B

Inventory Turnoveri存货周转率

5.56

正常

营业成本 (TTM) = $15.15B

平均存货 = $2.72B

Receivables Turnoveri应收账款周转率

4.06

正常

营收 (TTM) = $48.48B

平均应收账款 = $11.95B

S

偿债能力

Interest Coveragei利息保障倍数

10.33

健康

EBIT (TTM) = $10.49B

利息费用 (TTM) = $1.02B

Net Debt to EBITDAi净债务/EBITDA

2.53

正常

净债务 = $34.89B

EBITDA (TTM) = $13.78B

Debt Service Coveragei偿债覆盖率

5.77

健康

经营现金流 (TTM) = $13.31B

债务偿付 = $2.31B

V

价值指标

Goodwill %i商誉占比

25.1%

关注

商誉 = $21.74B

总资产 = $86.48B

Working Capital Ratioi营运资本比率

0.09

关注

营运资本 = $8.05B

总资产 = $86.48B

现金流瀑布图

加载图表中...

流入

流出

小计

起止点

C

现金流指标

经营现金流 TTMi

$13.31B

自由现金流 TTMi

$11.91B

FCF = OCF - CapEx

经营现金流 (TTM) = $13.31B

资本支出 (TTM) = $-1.40B

自由现金流收益率i

9.62%

关注

FCF (TTM) = $11.91B

市值 = $123.82B

经营现金流/销售比i

27.45%

健康

经营现金流 (TTM) = $13.31B

营业收入 (TTM) = $48.48B

Q

质量与覆盖指标

收益质量i

1.83x

健康

经营现金流 (TTM) = $13.31B

净利润 (TTM) = $7.28B

现金流/债务比i

0.30x

正常

经营现金流 (TTM) = $13.31B

总负债 = $44.46B

短期覆盖率i

0.69x

健康

经营现金流 (TTM) = $13.31B

流动负债 = $19.16B

资本支出覆盖率i

9.52x

健康

经营现金流 (TTM) = $13.31B

资本支出 (TTM) = $1.40B

E

效率指标

⚡ 比率按USD计算，去除汇率影响

自由/经营现金流比i

89.49%

健康

自由现金流 (TTM) = $11.91B

经营现金流 (TTM) = $13.31B

资本支出/营收比i

2.88%

健康

资本支出 (TTM) = $1.40B

营业收入 (TTM) = $48.48B

净债务/EBITDAi

2.53

正常

净债务 = $34.89B

EBITDA (TTM) = $13.78B

G

增长指标

经营现金流增长率i

-43.50%

关注

当期OCF (TTM) = $1.10B

上期OCF = $1.95B

股东盈余i

$9.47B

健康

净利润 (TTM) = $7.28B

+ 折旧摊销 (TTM) = $3.59B

- 资本支出 (TTM) = $-1.40B